NCT06361472 Contextual Factors-Enriched Standard Care on Mechanical Neck Pain
| NCT ID | NCT06361472 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad Nacional de la Matanza |
| Condition | Neck Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 94 participants |
| Start Date | 2024-05-02 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 94 participants in total. It began in 2024-05-02 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of this study will be to determine if a CFs-Enriched Standard Care approach is an effective treatment for mechanical neck pain in terms of reducing pain and improving function. We hypothesize that a 4-week CFs-Enriched Standard Care approach will be superior to Standard Care alone in terms of patient-reported disability and pain, with measurements conducted using the Northwick Park Neck Pain Questionnaire and the Numeric Pain Rating Scale, respectively. This will be an assessor-blinded, 2-group (1:1) randomized clinical trial aiming to enroll 94 participants with neck pain persisting for more than 4 weeks. Both groups will undergo 4 weeks of standard care twice weekly, following established clinical practice guidelines. In the intervention group, CFs will be enhanced, encompassing the physical, psychological, and social elements inherent in the clinical encounter, based on existing evidence. The primary outcomes will encompass changes in Pain and Disability after 4 weeks of treatment, with a follow-up reassessment at week 12 post-treatment. Secondary outcomes will include changes in Active Range of Motion, Global Rating of Change, and Satisfaction with treatment. The change between groups after treatment and at the 12-week follow-up will be reported for all outcomes, considering the difference from scores recorded at baseline. This study will be conducted at two sites in Buenos Aires, Argentina. Randomization will be stratified by site to ensure balanced allocation across centers.
Eligibility Criteria
Inclusion Criteria: * Aged \>18. * Neck pain for more than 4 weeks without signs or symptoms suggestive of major structural pathology. * Read, write, and understand the Spanish language. * Signed consent form. Exclusion Criteria: * Numeric Pain Reporting Scale (NPRS) \< 3 points (to ensure the exclusion of patients with minor disorders). * Northwick Park Neck Pain Questionnaire (NPQ) \< 10 points (to ensure the exclusion of patients with minor disorders). * History of cervical spine trauma, fracture, or surgical procedures. * Signs and symptoms of cervical myelopathy and/or cervical radiculopathy (to rule out cervical radicular pain, the Spurling Test, the Upper Limb Tension Test for the median nerve, and the Traction/Distraction test will be used). * Red flags or serious pathologies, such as malignancy, inflammatory or rheumatic diseases, infections, and vascular conditions like cervical artery insufficiency.
Contact & Investigator
Mauro F Andreu, PhD
PRINCIPAL INVESTIGATOR
Universidad Nacional de la Matanza
Frequently Asked Questions
Who can join the NCT06361472 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neck Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06361472 currently recruiting?
Yes, NCT06361472 is actively recruiting participants. Contact the research team at mfandreu@gmail.com for enrollment information.
Where is the NCT06361472 trial being conducted?
This trial is being conducted at Ciudad Autónoma de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina.
Who is sponsoring the NCT06361472 clinical trial?
NCT06361472 is sponsored by Universidad Nacional de la Matanza. The principal investigator is Mauro F Andreu, PhD at Universidad Nacional de la Matanza. The trial plans to enroll 94 participants.